---
title: "Why Are GJB2 Deafness Mice So Hard to Build? How TurboMice™ Breaks Through"
description: "Conventional techniques cannot produce homozygous GJB2/Cx26 deafness mice. VeloGene is the exclusive provider, delivering pure F0 homozygotes in 2 months for DFNB1 and other hearing-loss gene therapy studies."
featured_image: "https://velogene.com/wp-content/uploads/2026/11/GJB2.png"
url: "https://velogene.com/article/preclinical/turbomice-breaks-through-gjb2-deafness-mice/"
date_modified: "2026-11-03T16:44:15+08:00"
---

## VeloGene Biotechnology

### Exclusive GJB2 Deafness Mouse Model

---

# Why Are GJB2 Deafness Mice So Hard to Build? How TurboMice™ Breaks Through

Non-syndromic hearing loss (NSHL) is among the most common congenital birth defects, with over 60% of cases attributed to genetic factors. DFNB1 was the first genetic locus mapped for autosomal recessive non-syndromic hearing loss, located on human chromosome 13q11–q12. This region contains two genes, *GJB2* and *GJB6*, with *GJB2* being the predominant pathogenic gene at this locus.

Pathogenic variants in *GJB2* (Connexin 26, Cx26) account for approximately 10%–25% of autosomal recessive non-syndromic hearing loss. As clinical trials for gene therapies targeting *OTOF*, *GJB2* and other genes move forward, preclinical models that faithfully recapitulate human pathogenic variants have become a critical bottleneck for efficacy evaluation.

![GJB2](https://velogene.com/wp-content/uploads/2026/11/GJB2.png)
GJB2-Related Hearing Loss: Genotype-Phenotype Correlations, Natural History, and Emerging Therapeutic Strategies

---

---

---

## How GJB2 Variants Cause Deafness

The *GJB2* gene encodes connexin 26 (Cx26), which is highly expressed in cochlear supporting cells and keratinocytes. It mediates potassium ion recycling between adjacent cells, maintaining ionic homeostasis of inner ear fluids and the endocochlear potential.

When pathogenic variants disrupt *GJB2*, Cx26 expression is lost or dysfunctional, blocking potassium recirculation in the cochlea and lowering the endocochlear potential. Hair cells gradually undergo apoptosis due to impaired depolarization and metabolic dysfunction, ultimately leading to sensorineural hearing loss.

High-frequency pathogenic variants in the Chinese population include c.235delC (p.Gly79Valfs\*21), c.299\_300delAT (frameshift), c.176\_191del16 (deletion), and c.109G>A (p.Val37Ile), with c.235delC being the most prevalent pathogenic mutation in Chinese populations. In European and American populations, c.35delG (p.Gly12fs) is the most common.

## Limitations of Existing Mouse Models

Conventional *GJB2* deafness mice face a major bottleneck. Variants such as c.235delC, 35delG, and V37I are all recessive loss-of-function/nonsense mutations; heterozygotes show no phenotype, so homozygous models must be generated to recapitulate the disease.

However, placental development in mice is highly dependent on Cx26 gap junction channels for maternal–fetal nutrient transport (e.g., glucose). Placentae lacking functional *GJB2* fail to develop properly, causing embryonic death in mid-gestation. Conventional techniques therefore cannot obtain homozygotes through heterozygote intercrossing.

Leveraging TurboMice™ technology, MingCeler has successfully generated *GJB2* deafness mouse models. Tetraploid embryos develop exclusively into placental (extraembryonic) tissue, allowing diploid embryonic stem cells carrying homozygous deafness mutations to complete fetal development without relying on their own *GJB2* function — effectively circumventing in utero death caused by impaired maternal–fetal nutrient transport. TurboMice™ bypasses breeding and genotyping screening, delivering homozygous *GJB2* deafness mice in large batches in as little as 2 months.

## Other Deafness Genes

Beyond *GJB2*, non-syndromic hearing loss involves mutations in many other genes with diverse inheritance patterns:

(1) **Ion channel protein genes**, including *SLC26A4* and *TMC1*, which are critical for maintaining ionic and voltage homeostasis of inner ear fluids;

(2) **Extracellular matrix protein genes**, such as *TECTA*, which encodes tectorin — a major structural protein of the tectorial membrane;

(3) **Hair cell synaptic function proteins**:

The *OTOF* gene encodes otoferlin, a calcium-binding protein specific to cochlear ribbon synapses that acts as a calcium sensor driving vesicle exocytosis and fusion. *OTOF* mutations cause autosomal recessive deafness DFNB9, characterized by prelingual, moderate-to-profound hearing loss; some patients show temperature sensitivity.

The *SLC17A8* gene encodes Vglut3, which mediates glutamate vesicle loading at inner hair cell ribbon synapses and is essential for auditory pathway development and neurotransmission. Mutations cause excessively low synaptic glutamate levels, impairing action potential generation and resulting in autosomal dominant non-syndromic hearing loss DFNA25, clinically presenting as progressive high-frequency hearing loss.

![TurboMice Process](https://velogene.com/wp-content/uploads/2026/09/06a813d862ccabf3c5e7b904669d87f1.png)

## VeloGene Supports Deafness Gene Therapy

VeloGene’s proprietary TurboMice™ technology overcomes the long turnaround and low success rates historically associated with complex mouse models, generating fully homozygous gene-edited mice directly from embryonic stem cells in as little as 2 months.

MingCeler can customize a range of deafness mouse models based on specific pathogenic mutations, including but not limited to: **GJB2\* deafness mice, OTOF-/- mice, Vglut3 ** knockout mice, and \*Tmc1\* mutant mice. We welcome inquiries.

## Advatanges

Conventional GJB2 homozygotes die in mid-gestation due to placental Cx26 deficiency; TurboMice™ uses tetraploid placentas to support fully homozygous embryos without their own GJB2 function.

Directly derived from gene-edited ES cells — no heterozygote intercrossing, no genotyping, no chimeras.

Compared with 6+ months via conventional knock-in and breeding pipelines.

Hundreds of homozygous GJB2 deafness mice available for pharmacology, gene therapy efficacy and safety studies.

As of now, MingCeler is the only provider delivering homozygous GJB2 deafness mice, enabled solely by the proprietary TurboMice™ tetraploid complementation platform.

Also available on request for OTOF-/-, Vglut3 knockout, Tmc1 mutant, SLC26A4, TECTA and other hearing-loss genes.

Recreates high-frequency pathogenic variants including c.235delC, c.35delG, c.109G>A and other patient-relevant mutations.

## How to get your mice?

1

### Send Your Inquiry

Before we start, you can start by [submitting your inquiry form](https://velogene.com/contact-us/) or talk to us on our [Whatsapp](https://wa.me/85253737874) and tell us what you need! 

2

### Solution Design

We will reply to you as soon as possible and send you a quote!

3

### TurboMicing

We will get hands on your project.

4

### Get your Ready to Use f0 Mice!

Our f0 homozygous mice will ship to you and lab-ready!